Free Trial
NASDAQ:ORGS

Orgenesis (ORGS) Stock Price, News & Analysis

$0.74
+0.07 (+10.48%)
(As of 07/12/2024 ET)
Today's Range
$0.68
$0.85
50-Day Range
$0.45
$0.74
52-Week Range
$0.25
$1.33
Volume
488,047 shs
Average Volume
184,915 shs
Market Capitalization
$25.42 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A

Orgenesis MarketRank™ Stock Analysis

Analyst Rating
N/A
Upside/​Downside
N/A
Short Interest
Healthy
0.79% of Shares Sold Short
Dividend Strength
N/A
Sustainability
-1.49
Upright™ Environmental Score
News Sentiment
0.44mentions of Orgenesis in the last 14 days
Based on 2 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
N/A

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

1.14 out of 5 stars

Medical Sector

774th out of 912 stocks

Pharmaceutical Preparations Industry

364th out of 434 stocks

ORGS stock logo

About Orgenesis Stock (NASDAQ:ORGS)

Orgenesis Inc., a biotech company, focuses on cell and gene therapies worldwide. It operates through two segments, Octomera and Therapies. The company develops a Point of Care (POCare) platform that includes a pipeline of licensed cell based POCare therapies that are processed and produced under closed and automated POCare technology systems across a collaborative POCare network consisting of research institutes and hospitals. Its therapies include autologous; cell-based immunotherapies; and therapeutics for metabolic diseases, anti-viral diseases, and tissue regeneration. The company also provides development services, including regulatory services, pre-clinical studies, intellectual property services, and GMP process translation, as well as support services; hospital services; cell process development services; and distributed cell processing services. The company was formerly known as Business Outsourcing Service, Inc. and changed its name to Orgenesis Inc. in August 2011. Orgenesis Inc. was incorporated in 2008 and is headquartered in Germantown, Maryland.

ORGS Stock Price History

ORGS Stock News Headlines

This litigation is a blessing in disguise
This may be one of the most bizarre situations I’ve ever seen. One stock on the NASDAQ is now trading for $10. What’s so unusual is that this company has a market cap of $8 billion and $9 billion in cash.
Orgenesis Provides Year End Business Update
This litigation is a blessing in disguise
This may be one of the most bizarre situations I’ve ever seen. One stock on the NASDAQ is now trading for $10. What’s so unusual is that this company has a market cap of $8 billion and $9 billion in cash.
Orgenesis Inc. (ORGS)
Orgenesis Inc ORGS
See More Headlines
Receive ORGS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Orgenesis and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
5/21/2024
Today
7/14/2024
Next Earnings (Estimated)
8/09/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:ORGS
Fax
N/A
Employees
146
Year Founded
2008

Profitability

Net Income
$-55,360,000.00
Net Margins
-1,343.97%
Pretax Margin
-692.54%

Debt

Sales & Book Value

Annual Sales
$530,000.00
Book Value
($0.66) per share

Miscellaneous

Free Float
32,497,000
Market Cap
$25.42 million
Optionable
Optionable
Beta
1.23

Social Links

Ten Starter Stocks For Beginners to Buy Now Cover

Just getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.

Get This Free Report

Key Executives

  • Ms. Vered Caplan M.Sc. (Age 55)
    Chairperson of the Board, CEO & President
    Comp: $341.38k
  • Prof. Sarah Ferber Ph.D. (Age 70)
    Founder & Chief Scientific Officer
    Comp: $268.32k
  • Mr. Victor Miller (Age 54)
    CFO, Secretary & Treasurer
  • Pierre Lammeretz
    Interim Chief Operating Officer
  • Dr. Shimon Hassin Ph.D.
    Chief Technology Officer
  • Mr. Evan Fishman
    Chief Financial Officer of Orgenesis Biotech
  • Mr. Joseph Carpinelli
    Chief Financial Officer of Octomera

ORGS Stock Analysis - Frequently Asked Questions

How have ORGS shares performed this year?

Orgenesis' stock was trading at $0.5007 at the beginning of the year. Since then, ORGS shares have increased by 47.4% and is now trading at $0.7380.
View the best growth stocks for 2024 here
.

How were Orgenesis' earnings last quarter?

Orgenesis Inc. (NASDAQ:ORGS) issued its quarterly earnings data on Tuesday, May, 21st. The company reported ($0.29) earnings per share (EPS) for the quarter. The business earned $0.14 million during the quarter.

Does Orgenesis have any subsidiaries?

The following companies are subsidiaries of Orgenesis: Koligo Therapeutics, and Tamir Biotechnology Inc.

How do I buy shares of Orgenesis?

Shares of ORGS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:ORGS) was last updated on 7/14/2024 by MarketBeat.com Staff

From Our Partners